NASDAQ · IVFHealthcareSurgical Instruments

INVO Fertility financials

$0.9110−2.42%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Revenue$2.2M$2.0M$1.6M$1.8M$1.9M
Gross profit$762.7K$727.8K$536.9K$629.3K$770.1K
Gross margin35.1%36.1%33.9%35.8%41.3%
Operating income-$1.3M-$1.6M-$1.4M-$1.6M-$3.0M
Net income$888.7K-$5.5M$202.8K-$2.6M-$3.6M
Net margin40.9%−274.9%12.8%−150.5%−194.2%
Diluted EPS$0.35$-3.38—$-0.77$-364.23
EBITDA-$1.1M-$1.4M-$1.3M-$1.5M-$1.4M
Operating cash flow-$1.1M-$1.9M$25.2K-$1.8M-$1.7M
Free cash flow-$1.1M-$1.9M$13.4K-$1.8M-$1.7M
Diluted shares2.6M1.6M—3.4M0.0M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30
Cash & equivalents$3.7M$4.9M$2.1M$355.9K$549.2K
Short-term investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.6M$1.0M$2.0M$1.1M$3.9M
Total assets$25.8M$24.7M$20.2M$18.8M$19.3M
Total liabilities$9.3M$9.6M$13.0M$13.0M$16.7M
Shareholders' equity$16.5M$15.0M$7.2M$5.8M$2.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology